Acrivon Therapeutics Acquires Janus Kinase 1 Inhibitor ACR-525 From Aqilion AB; Terms Undisclosed

Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative AI-driven Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced that it has acquired ACR-525 (formerly known as AQ280), a Phase 2-ready, oral, highly selective Janus kinase 1 (JAK1) inhibitor, and a protein kinase C theta (PKCθ) inhibitor preclinical program, from Aqilion AB ("Aqilion"). The acquisition establishes I&I as a strategic pillar for Acrivon alongside its oncology programs.